Reference

Use of orotic acid for prevention or therapy of remodeling in acute infarct patients

Use of orotic acid for prevention or therapy of remodeling in acute infarct patients. Woerwag, Fritz (Woerwag Pharma Gmbh, Germany). Ger. Offen. DE 19530278 A1 20 Feb 1997, 6 pp. (German). (Germany). CODEN: GWXXBX. CLASS: ICM: A61K031-505. APPLICATION: DE 1995-19530278 17 Aug 1995. DOCUMENT TYPE: Patent CA Section: 1 (Pharmacology) Structural changes in cardiac tissue surrounding an infarct site, e.g. left ventricle dilatation, which may ultimately lead to heart failure are prevented by administration of orotic acid. Thus, in coronary heart disease patients with compromised left ventricular function (due in some cases to myocardial infarction) who received Mg orotate (2 500-mg tablets 3 times a day), performance was improved, as indicated by decreases in left ventricular end-systolic and end-diastolic vols. and an increase in ejection fraction. 85637-73-6 and 34717-03-8 are just another two chemicals used in this study. .

Use of orotic acid for prevention and treatment of metabolic syndrome

Use of orotic acid for prevention and treatment of metabolic syndrome. Woerwag, Fritz (Woerwag Pharma Gmbh, Germany). Ger. Offen. DE 19530298 A1 20 Feb 1997, 5 pp. (German). (Germany). CODEN: GWXXBX. CLASS: ICM: A61K031-505. APPLICATION: DE 1995-19530298 17 Aug 1995. DOCUMENT TYPE: Patent CA Section: 1 (Pharmacology) Hypertension, obesity, diabetes mellitus, and disturbances in lipid metab., collectively referred to as metabolic syndrome, can be successfully treated or prevented with orotic acid and its salts. Thus, triathletes with Mg orotate supplementation (17 mmol/day for 4 wk) showed improved insulin-dependent glucose utilization and elevated renal urate elimination during exercise. 65-86-1 and 34717-03-8 are just another two chemicals used in this study. .